InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.47
(
0.10%
)
Bitcoin
61,100.88
(
-0.57%
)
Post# of 12943
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Wildbilly

Send PM Follow Ignore
Followers 231
Posts 34993
Boards Moderated 1
Alias Born 11/19/2003

Wildbilly

Re: None

Thursday, 09/22/2016 5:29:04 AM

Thursday, September 22, 2016 5:29:04 AM

Post# of 12943
Whaaaat? SRPT, this one has it all,

approval on a failed study, offering after hours (natch, SOP), accusations of a con, insane move in the pps, surely a pricing controversy will be in the cards( derigueur now after MYL's stock went up AH as the CEO was being hammered in front of congress) and now this, calls for a retraction.

Amid controversial Sarepta approval decision, FDA head calls for key study retraction - Retraction Watch at Retraction Watch
http://retractionwatch.com/2016/09/21/amid-controversial-sarepta-approval-decision-fda-head-calls-for-key-study-retraction/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up